These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25572908)

  • 21. Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute.
    Jun E; Kim SC; Song KB; Hwang DW; Lee JH; Shin SH; Hong SM; Park KM; Lee YJ
    Surgery; 2017 Jul; 162(1):120-130. PubMed ID: 28262254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
    Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
    BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor.
    Xu SS; Xu HX; Wang WQ; Li S; Li H; Li TJ; Zhang WH; Liu L; Yu XJ
    World J Gastroenterol; 2019 Nov; 25(41):6248-6257. PubMed ID: 31749595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
    Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
    Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
    Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors.
    Cheng Y; Sun Z; Bai C; Yan X; Qin R; Meng C; Ying H
    Tumour Biol; 2016 Mar; 37(3):2863-9. PubMed ID: 26408184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
    Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors.
    Namwongprom S; Wong FC; Tateishi U; Kim EE; Boonyaprapa S
    Ann Nucl Med; 2008 May; 22(4):237-43. PubMed ID: 18535873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
    Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
    Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm.
    Paik WH; Ryu JK; Song BJ; Kim J; Park JK; Kim YT; Yoon YB
    J Korean Med Sci; 2013 May; 28(5):750-4. PubMed ID: 23678268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The predictive value of mean platelet volume in differential diagnosis of non-functional pancreatic neuroendocrine tumors from pancreatic adenocarcinomas.
    Karaman K; Bostanci EB; Aksoy E; Kurt M; Celep B; Ulas M; Dalgic T; Surmelioglu A; Hayran M; Akoglu M
    Eur J Intern Med; 2011 Dec; 22(6):e95-8. PubMed ID: 22075321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors.
    Jensen KH; Hilsted L; Jensen C; Mynster T; Rehfeld JF; Knigge U
    Scand J Gastroenterol; 2013 Jan; 48(1):70-7. PubMed ID: 23094948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.
    Massironi S; Conte D; Sciola V; Spampatti MP; Ciafardini C; Valenti L; Rossi RE; Peracchi M
    Am J Gastroenterol; 2010 Sep; 105(9):2072-8. PubMed ID: 20372113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
    Rustagi S; Warner RR; Divino CM
    J Surg Oncol; 2013 Aug; 108(2):126-8. PubMed ID: 23775817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.
    Arnold R; Wilke A; Rinke A; Mayer C; Kann PH; Klose KJ; Scherag A; Hahmann M; Müller HH; Barth P
    Clin Gastroenterol Hepatol; 2008 Jul; 6(7):820-7. PubMed ID: 18547872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Usefulness of chromogranin A determination in the diagnosis of neuroendocrine neoplasia].
    Militello C; Cannizzaro R; Pradella P; Volpin E; Spirch S; Buonadonna A; De Appollonia L; Rossi C; Sigon R; Cipresso S; Terranova O
    Chir Ital; 1999; 51(1):45-51. PubMed ID: 10514916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report.
    Kos-Kudła B; Zemczak A; Foltyn W; Marek B; Strzelczyk J; Telega A; Zajecki W; Legaszewski T; Jurecka-Lubieniecka B
    Endokrynol Pol; 2007; 58(2):123-9. PubMed ID: 17578828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chromogranin A and neuroendocrine tumors].
    Díaz Pérez JÁ; Currás Freixes M
    Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.